

University of Groningen

Corrigendum to "Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients with asthma" [Pulm. Pharmacol. Therapeut. 70 (2021) 102068]

Buhl, Roland; Nikolaev, Ivan; Tillmann, Hanns-Christian; Vaidya, Soniya; Bartels, Christian; Jain, Monish; Jauernig, Juergen; Kerstjens, Huib A M

Published in:
 Pulmonary Pharmacology & Therapeutics

DOI:
[10.1016/j.pupt.2022.102126](https://doi.org/10.1016/j.pupt.2022.102126)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
 Publisher's PDF, also known as Version of record

Publication date:
 2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Buhl, R., Nikolaev, I., Tillmann, H-C., Vaidya, S., Bartels, C., Jain, M., Jauernig, J., & Kerstjens, H. A. M. (2022). Corrigendum to "Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients with asthma" [Pulm. Pharmacol. Therapeut. 70 (2021) 102068]. *Pulmonary Pharmacology & Therapeutics*, 73-74, [102126]. <https://doi.org/10.1016/j.pupt.2022.102126>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).


The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Contents lists available at [ScienceDirect](#)

Pulmonary Pharmacology & Therapeutics

journal homepage: www.elsevier.com/locate/ypupt

Corrigendum to “Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients with asthma” [Pulm. Pharmacol. Therapeut. 70 (2021) 102068]

Roland Buhl^a, Ivan Nikolaev^b, Hanns-Christian Tillmann^{c,*}, Soniya Vaidya^{d,e}, Christian Bartels^b, Monish Jain^d, Juergen Jauernig^b, Huib A.M. Kerstjens^f

^a Pulmonary Department, Mainz University Hospital, Mainz, Germany

^b Novartis Pharma AG, Basel, Switzerland

^c Novartis Institutes for BioMedical Research, Translational Medicine, Basel, Switzerland

^d Novartis Institutes for BioMedical Research, Cambridge, MA, USA

^e Axcella Health Inc., Cambridge, MA, USA

^f University of Groningen, University Medical Center Groningen and Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands

The authors regret incorrectly citing:

- Moore WC et al. instead of ‘Global strategy for asthma management and prevention. 2020’ for the following sentence in the introduction: *In addition, add-on therapy with a long-acting muscarinic antagonist (LAMA) is suggested in patients inadequately controlled on ICS/LABA.*
- Kerstjens HAM et al. instead of ‘Bartels C et al. Eur J Drug Metab Pharmacokinet. 46(4) (2021) 487–504’ for the following sentence: A

population PK analysis of the Phase III PK data was conducted, which also assessed the systemic exposure (C_{max}, C_{trough}) of the different MF doses in the combination therapies of MF/IND and MF/IND/GLY delivered via the Breezhaler® device in patients with asthma. The analysis included 279 patients.

The corrected references have been updated in the online version. The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.pupt.2021.102068>.

* Corresponding author.

E-mail address: hanns-christian.tillmann@novartis.com (H.-C. Tillmann).

<https://doi.org/10.1016/j.pupt.2022.102126>

Available online 11 April 2022

1094-5539/© 2022 The Author(s). Published by Elsevier Ltd. All rights reserved.